Wai Chun Bio-Technology delays FY2026 results; board meeting moved to 13 Nov amid ongoing trading suspension

Bulletin Express

Nov 04

Wai Chun Bio-Technology Limited has postponed its planned board meeting to 13 November 2026 after its independent auditor requested more time to complete key audit procedures for the financial year ended 30 June 2026.

According to the company’s 4 November filing, the outstanding audit work focuses on: 1. Review of valuation and other significant accounting estimates. 2. Completion of bank and third-party confirmation procedures.

As a result, publication of the audited FY2026 annual results will be further delayed. Trading in Wai Chun Bio-Technology shares has been suspended since 9:00 a.m. on 2 October 2026 and will remain halted until the results are released.

The board advises shareholders and prospective investors to exercise caution when dealing in the company’s securities.

Wai Chun Bio-Technology’s board currently comprises one executive director—Chairman and CEO Lam Ka Chun—and three independent non-executive directors: Wong Po Keung, Wang Ziniu and Xu Huiling.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1131101568"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131101568\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131101568?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-04 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131101568","market":"us","top_or_hot":-1,"title":"Wai Chun Bio-Technology delays FY2026 results; board meeting moved to 13 Nov amid ongoing trading suspension","media":"Bulletin Express","content":"<p>Wai Chun Bio-Technology Limited has postponed its planned board meeting to 13 November 2026 after its independent auditor requested more time to complete key audit procedures for the financial year ended 30 June 2026.</p>\n<p>According to the company’s 4 November filing, the outstanding audit work focuses on:  \n1. Review of valuation and other significant accounting estimates.  \n2. Completion of bank and third-party confirmation procedures.</p>\n<p>As a result, publication of the audited FY2026 annual results will be further delayed. Trading in Wai Chun Bio-Technology shares has been suspended since 9:00 a.m. on 2 October 2026 and will remain halted until the results are released.</p>\n<p>The board advises shareholders and prospective investors to exercise caution when dealing in the company’s securities.</p>\n<p>Wai Chun Bio-Technology’s board currently comprises one executive director—Chairman and CEO Lam Ka Chun—and three independent non-executive directors: Wong Po Keung, Wang Ziniu and Xu Huiling.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wai Chun Bio-Technology delays FY2026 results; board meeting moved to 13 Nov amid ongoing trading suspension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWai Chun Bio-Technology delays FY2026 results; board meeting moved to 13 Nov amid ongoing trading suspension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-11-04 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wai Chun Bio-Technology Limited has postponed its planned board meeting to 13 November 2026 after its independent auditor requested more time to complete key audit procedures for the financial year ended 30 June 2026.</p>\n<p>According to the company’s 4 November filing, the outstanding audit work focuses on:  \n1. Review of valuation and other significant accounting estimates.  \n2. Completion of bank and third-party confirmation procedures.</p>\n<p>As a result, publication of the audited FY2026 annual results will be further delayed. Trading in Wai Chun Bio-Technology shares has been suspended since 9:00 a.m. on 2 October 2026 and will remain halted until the results are released.</p>\n<p>The board advises shareholders and prospective investors to exercise caution when dealing in the company’s securities.</p>\n<p>Wai Chun Bio-Technology’s board currently comprises one executive director—Chairman and CEO Lam Ka Chun—and three independent non-executive directors: Wong Po Keung, Wang Ziniu and Xu Huiling.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00660","symbol_name":"玮俊生物科技","start_time":0,"source_url":"","article_id":"1131101568","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131101568","pubTimestamp":1793786555,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Wai Chun Bio-Technology Limited has postponed its planned board meeting to 13 November 2026 after its independent auditor requested more time to complete key audit procedures for the financial year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00660":"玮俊生物科技"},"translate_title":"伟俊生物科技推迟 2026 财年业绩；由于持续停牌，董事会会议推迟至 11 月 13 日","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00660":1},"content_text":"Wai Chun Bio-Technology Limited has postponed its planned board meeting to 13 November 2026 after its independent auditor requested more time to complete key audit procedures for the financial year ended 30 June 2026.\nAccording to the company’s 4 November filing, the outstanding audit work focuses on:  \n1. Review of valuation and other significant accounting estimates.  \n2. Completion of bank and third-party confirmation procedures.\nAs a result, publication of the audited FY2026 annual results will be further delayed. Trading in Wai Chun Bio-Technology shares has been suspended since 9:00 a.m. on 2 October 2026 and will remain halted until the results are released.\nThe board advises shareholders and prospective investors to exercise caution when dealing in the company’s securities.\nWai Chun Bio-Technology’s board currently comprises one executive director—Chairman and CEO Lam Ka Chun—and three independent non-executive directors: Wong Po Keung, Wang Ziniu and Xu Huiling.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}